Head-to-head · WeighScore
Claya vs Medsol RX
The verdict
Claya takes it — 62.8/100 to 61/100, but only just.
Claya grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Claya is a direct-to-consumer telehealth platform offering compounded semaglutide and tirzepatide in both injectable and oral-tablet forms — a wider format range than most competitors. Medsol RX is close behind and may still be the better fit — see the factor split below.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Claya | Medsol RX |
|---|---|---|
| WeighScore | 62.8/100 | 61/100 |
| Grade | C | C |
| Scorecard rank | #268 | #306 |
| Semaglutide | $299/mo (compounded) | $209/mo (compounded) |
| Tirzepatide | $299/mo (compounded) | $250/mo (compounded) |
| Coverage | Coverage not published | All 50 states |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Yes | Injection only |
Graded #268 · C
Strengths
- Two named licensed clinicians (Habashy, NMD MS and Barber, MD PhD) — rare transparency for compounded GLP-1
- Two named pharmacy partners with full addresses (RedRock, UT and Healthware, KY)
- Both injectable and oral-tablet forms offered for semaglutide and tirzepatide
- Weight-loss money-back guarantee published on the homepage
- Free expedited shipping included in the monthly price
Where it loses points
- States-served list not disclosed — you must check at checkout
- LegitScript certification status not displayed
- Corporate legal entity not disclosed on the site or privacy policy
- Oral compounded tablets have weaker efficacy data than injectable semaglutide
- Intro pricing is higher at refill ($299), erasing the first-month advantage
Graded #306 · C
Strengths
- Compounded semaglutide from $209/mo (12-mo plan) and tirzepatide from ~$250/mo; HSA/FSA eligible with Klarna financing
- Every plan bundles the medication, a dedicated care coach, custom treatment plan, medical oversight, and free shipping
- Board-certified clinicians via OpenLoop; same-day approvals; ships nationwide
- Month-to-month option ($199 first month) with no long-term commitment, plus microdosing and wellness add-ons
Where it loses points
- Doesn't name its compounding pharmacy (generic 'certified U.S. pharmacies')
- No legal entity name published on the site
- Tirzepatide pricing is given as a range ($250-$1,400/mo), not a fixed rate
- Compounded GLP-1s are not FDA-approved (the site discloses this)
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.